A Peek Into the Future: Will Serial Multimarker Testing Help Bring a New Era of Precision Medicine in Heart Failure Patients?

HomeCirculation: Heart FailureVol. 16, No. 1A Peek Into the Future: Will Serial Multimarker Testing Help Bring a New Era of Precision Medicine in Heart Failure Patients? No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextA Peek Into the Future: Will Serial Multimarker Testing Help Bring a New Era of Precision Medicine in Heart Failure Patients? James A. Alzate, Pradeep S. Rajendran and Hanna K. Gaggin James A. AlzateJames A. Alzate https://orcid.org/0000-0002-3021-8276 Department of Medicine (J.A.A., P.S.R.), Massachusetts General Hospital, Boston, MA. Harvard Medical School, Boston, MA (J.A.A., P.S.R., H.K.G.). Search for more papers by this author , Pradeep S. RajendranPradeep S. Rajendran https://orcid.org/0000-0001-9790-0408 Department of Medicine (J.A.A., P.S.R.), Massachusetts General Hospital, Boston, MA. Harvard Medical School, Boston, MA (J.A.A., P.S.R., H.K.G.). Search for more papers by this author and Hanna K. GagginHanna K. Gaggin Correspondence to: Hanna K. Gaggin, MD, MPH, Cardiology Division, Massachusetts General Hospital, 55 Fruit St, Yawkey 5B, Boston, MA 02114. Email E-mail Address: [email protected] https://orcid.org/0000-0001-8068-6134 Division of Cardiology, Corrigan Minehan Heart Center (H.K.G.), Massachusetts General Hospital, Boston, MA. Harvard Medical School, Boston, MA (J.A.A., P.S.R., H.K.G.). Search for more papers by this author Originally published21 Nov 2022https://doi.org/10.1161/CIRCHEARTFAILURE.122.010156Circulation: Heart Failure. 2023;16This article is a commentary on the followingMultimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart FailureFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 43.Correspondence to: Hanna K. Gaggin, MD, MPH, Cardiology Division, Massachusetts General Hospital, 55 Fruit St, Yawkey 5B, Boston, MA 02114. Email [email protected]harvard.eduReferences1. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Circulation. 2022; 145:e895–e1032. doi: 10.1161/CIR.0000000000001063LinkGoogle Scholar2. Meijers WC, Bayes-Genis A, Mebazaa A, Bauersachs J, Cleland JGF, Coats AJS, Januzzi JL, Maisel AS, McDonald K, Mueller T, et al. Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).Eur J Heart Fail. 2021; 23:1610–1632. doi: 10.1002/ejhf.2346CrossrefMedlineGoogle Scholar3. Demissei BG, Cotter G, Prescott MF, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Severin TM, Wang Y, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.Eur J Heart Fail. 2017; 19:1001–1010. doi: 10.1002/ejhf.749CrossrefMedlineGoogle Scholar4. Gürgöze MT, van Vark LC, Baart SJ, Kardys I, Akkerhuis KM, Manintveld OC, Postmus D, Hilleg HL, LesmanLeegte I, Asselberg FW, et al. Multi-marker analysis of serially measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, creatinine and prognosis in acute heart failure.Circ Heart Fail. 2023; 16:27–40. doi: 10.1161/CIRCHEARTFAILURE.122.009526.LinkGoogle Scholar5. Wang D, Day EA, Townsend LK, Djordjevic D, Jørgensen SB, Steinberg GR. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease.Nat Rev Endocrinol. 2021; 17:592–607. doi: 10.1038/s41574-021-00529-7CrossrefMedlineGoogle Scholar6. Kuster N, Huet F, Dupuy AM, Akodad M, Battistella P, Agullo A, Leclercq F, Kalmanovich E, Meilhac A, Aguilhon S, et al. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure.ESC Heart Fail. 2020; 7:2230–2239. doi: 10.1002/ehf2.12680CrossrefMedlineGoogle Scholar7. Januzzi JL, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.J Am Coll Cardiol. 2011; 58:1881–1889. doi: 10.1016/j.jacc.2011.03.072CrossrefMedlineGoogle Scholar8. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, et al; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.JAMA. 2009; 301:383–392. doi: 10.1001/jama.2009.2CrossrefMedlineGoogle Scholar9. Felker GM, Anstrom KJ, Adams KF, Ezekowitz JA, Fiuzat M, Houston-Miller N, Januzzi JL, Mark DB, Piña IL, Passmore G, et al. Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: a randomized clinical trial.JAMA. 2017; 318:713–720. doi: 10.1001/jama.2017.10565CrossrefMedlineGoogle Scholar10. Stienen S, Salah K, Moons AH, Bakx AL, van Pol P, Kortz RAM, Ferreira JP, Marques I, Schroeder-Tanka JM, Keijer JT, et al. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?).Circulation. 2018; 137:1671–1683. doi: 10.1161/CIRCULATIONAHA.117.029882LinkGoogle Scholar11. Omar M, Jensen J, Kistorp C, Højlund K, Videbæk L, Tuxen C, Larsen JH, Andersen CF, Gustafsson F, Køber L, et al. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure: a randomized controlled trial (Empire HF Biomarker).Cardiovasc Diabetol. 2022; 21:34. doi: 10.1186/s12933-022-01463-2CrossrefMedlineGoogle Scholar12. Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O’Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL; PARADIGM-HF Investigators and Committees. PARADIGM-HF Investigators and Committees. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial.Eur J Heart Fail. 2018; 20:1701–1709. doi: 10.1002/ejhf.1301CrossrefMedlineGoogle Scholar13. Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J, Chioncel O, Solal AC, Diaz R, Damasceno A, et al. Safety, tolerability and efficacy of rapid optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study.Eur J Heart Fail. 2019; 21:1459–1467. doi: 10.1002/ejhf.1575CrossrefMedlineGoogle Scholar14. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, et al; VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction.N Engl J Med. 2020; 382:1883–1893. doi: 10.1056/NEJMoa1915928CrossrefMedlineGoogle Scholar15. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sørensen T, et al; GALACTIC-HF Investigators. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure.N Engl J Med. 2021; 384:105–116. doi: 10.1056/NEJMoa2025797CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesMultimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart FailureMuhammed T. Gürgöze, et al. Circulation: Heart Failure. 2023;16 January 2023Vol 16, Issue 1 Advertisement Article InformationMetrics © 2022 American Heart Association, Inc.https://doi.org/10.1161/CIRCHEARTFAILURE.122.010156PMID: 36408700 Originally publishedNovember 21, 2022 Keywordsprognosisprecision medicinebiomarkersEditorialsheart failureNTproBNPGDF-15hospitalizationPDF download Advertisement